The original success of the copyright undeniably transformed the drug landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. While early profits were substantial, the cessation of patents and the rise of less expensive alternatives have eroded the customer base. Consequently, a thorough evalu